Abstract
Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.
| Original language | English |
|---|---|
| Pages (from-to) | 147-153 |
| Number of pages | 7 |
| Journal | Experimental and Molecular Pathology |
| Volume | 93 |
| Issue number | 1 |
| DOIs | |
| State | Published - Aug 2012 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry
- Molecular Biology
- Pathology and Forensic Medicine
Cite this
Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma. / Trowbridge, Ryan; Sharma, Poonam K; Hunter, William J.; Agrawal, Devendra K.
In: Experimental and Molecular Pathology, Vol. 93, No. 1, 08.2012, p. 147-153.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma
AU - Trowbridge, Ryan
AU - Sharma, Poonam K
AU - Hunter, William J.
AU - Agrawal, Devendra K.
PY - 2012/8
Y1 - 2012/8
N2 - Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.
AB - Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.
UR - http://www.scopus.com/inward/record.url?scp=84860821724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860821724&partnerID=8YFLogxK
U2 - 10.1016/j.yexmp.2012.04.018
DO - 10.1016/j.yexmp.2012.04.018
M3 - Article
C2 - 22546272
AN - SCOPUS:84860821724
VL - 93
SP - 147
EP - 153
JO - Experimental and Molecular Pathology
JF - Experimental and Molecular Pathology
SN - 0014-4800
IS - 1
ER -